retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Phase 2 trial results demonstrate

Injectables can over-plump or distort facial contours if not done carefully, and surgical options are invasive and irreversible

Find articles by Zanchi, D

Wegovy (semaglutide injection) Product Monograph

No need to step through the lower doses again.It's a straightforward switch and for many, probably a welcome one.The MHRA's approval marks the first time a GLP-1 tablet of this kind has been cleared for use in the UK, and it signals a broader shift in how weight management treatment might look in the years ahead

Most do not find differences in sweet taste perception between individuals with and without obesity

Communication is text-based through their platform